TYK Medicines Inc. has synthesized cyclin-dependent kinase 4 (CDK4) inhibitors designed for use in the treatment of cancer, infections, and metabolic, inflammatory cardiovascular and inflammatory disorders.
Arvinas Operations Inc. has disclosed proteolysis targeting chimera (PROTACs) compounds comprising a cereblon (CRBN) E3 ubiquitin ligase-binding moiety covalently linked to a B-cell lymphoma 6 protein (BCL-6)-targeting moiety through a linker with potential for use in the treatment of cancer.
Rybodyn Inc. has announced the initial close of a $10 million seed financing to support its work decoding the dark proteome using an AI-powered novel sequencing and discovery platform. The financing will accelerate the company’s transition from foundational discovery into scaled platform execution and progress early-stage programs into IND-enabling studies.
Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer, arising from abnormal proliferation of epidermal keratinocytes due to chronic UV exposure. While highly curable (>90%) with surgical excision when detected early, it carries a significant risk of local invasion and metastasis if left untreated.
Simcere Zaiming Pharmaceutical Co. Ltd. has synthesized coumarin compounds targeting mitogen-activated protein kinase kinase reported to be useful for the treatment of cancer.
The Council of Scientific and Industrial Research has disclosed poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.
Scientists from Nanyang Biologics Pte. Ltd. and Nanyang Technological University have divulged molephantinin derivatives reported to be useful for the treatment of colorectal cancer.
Overt Bio Inc. is advancing lead asset OVT-101 toward the clinic. The allogeneic, potential first-in-class, off-the-shelf γδ CAR T therapy targets claudin-6, which is present in the majority of ovarian cancers and several other solid tumors.
RSS
